Biogen seeks new chief, cuts Aduhelm spending
Biogen will replace its chief executive officer and largely abandon marketing of its controversial Alzheimer's drug Aduhelm less than a year after the medication's release triggere…
Biogen will replace its chief executive officer and largely abandon marketing of its controversial Alzheimer's drug Aduhelm less than a year after the medication's release triggere…